Humira (adalimumab) / AbbVie 
Welcome,         Profile    Billing    Logout  
 200 Diseases   176 Trials   176 Trials   22029 News 


12345678910111213...238239»
  • ||||||||||  tofacitinib / Generic mfg., Humira (adalimumab) / AbbVie
    Journal:  Darier's Disease Successfully Treated with Tofacitinib: A Case Report. (Pubmed Central) -  Dec 1, 2025   
    After a few months, with most lesions resolved, the dose was reduced to 10 mg daily, successfully maintaining disease control. This report highlights the potential role of JAK inhibitors as an effective treatment option for refractory DD.
  • ||||||||||  Humira (adalimumab) / AbbVie, Tremfya (guselkumab) / J&J
    Systemic Biologic Treatment for Psoriasis in Elderly Patients () -  Nov 28, 2025 - Abstract #ISDS2025ISDS_325;    
    Biologic treatments for psoriasis demonstrate both efficacy and safety in elderly patients. Some agents exhibited better drug survival when initiated after age 65 years.
  • ||||||||||  Common Psoriasis Therapeutics and Ocular Symptoms: Analysis of the FAERS Database () -  Nov 28, 2025 - Abstract #ISDS2025ISDS_319;    
    Apremilast, however, was only associated with increased risk of blepharospasm (16.43); all other adverse events studied displayed no increased risk. Our findings support the necessity of physician guidance and the research needed in elucidating ocular adverse events.
  • ||||||||||  Humira (adalimumab) / AbbVie, Cosentyx (secukinumab) / Novartis, Tavalisse (fostamatinib) / Rigel
    Targeting B-cells in Hidradenitis Suppurativa: A Systematic Review of Bruton's Tyrosine Kinase Inhibition as a Target () -  Nov 28, 2025 - Abstract #ISDS2025ISDS_265;    
    Adalimumab and secukinumab remain the only FDA approved biologic, but many patients experience suboptimal control...While no published BTKi studies in HS exist, a small proof-of-concept trial of the spleen tyrosine kinase inhibitor fostamatinib reported Hidradenitis Suppurativa Clinical Response score (HiSCR) achievement in 85% of participants by week 4...This review underscores an urgent need to expand therapeutic options for patients with refractory disease. Keywords: tyrosine kinase inhibitors, hidradenitis suppurativa, B-cell signaling, Bruton's tyrosine kinase
  • ||||||||||  sonelokimab (M1095) / Avillion, MoonLake Immunotherap
    Decoding the IL-17 axis in hidradenitis suppurativa: Pharmacodynamic profiling of the Nanobody () -  Nov 28, 2025 - Abstract #ISDS2025ISDS_154;    
    P2
    IL-19 and PI3 are robust pharmacodynamic IL-17 pathway biomarkers of disease activity in HS. Their normalization following sonelokimab treatment underscores the drug's targeted mechanism of action and supports their potential utility in monitoring therapeutic response, further validating IL-17A and IL-17F as central drivers of HS pathogenesis.
  • ||||||||||  Nucala (mepolizumab) / GSK, Humira (adalimumab) / AbbVie, Fasenra (benralizumab) / AstraZeneca
    Shifting COPD and asthma care left: analysis of the 'one stop' community diagnostic clinic in the West of Ireland (Cambridge/5th) -  Nov 28, 2025 - Abstract #BTSWM2025BTS_WM_555;    
    Eight patients retained good asthma control whilst receiving dual Mab therapy, with one patient stopping mepolizumab at 12 months due to poor asthma response...Dual biologic prescribing, furthermore, did not appear to affect asthma control. Further real-world data are required, and use of national registry data could be used to generate more robust safety data.
  • ||||||||||  Humira (adalimumab) / AbbVie
    Journal:  Impact of adalimumab treatment on impairment of non-professional activities in psoriasis patients. (Pubmed Central) -  Nov 28, 2025   
    We demonstrate a higher rate of treatment cessation in the RA-ILD group than was seen in the INBUILD study warranting more research to understand whether this relates to disease severity at initiation or the co-prescription of DMARDs. Long-term treatment with adalimumab had a favorable impact on clinical outcomes, employment-related aspects, practice of non-professional activities, and health-related quality of life in psoriasis patients.
  • ||||||||||  Remicade (infliximab) / J&J, methotrexate / Generic mfg., Humira (adalimumab) / AbbVie
    Journal:  Atypical waves: nonsporotrichoid Mycobacterium marinum skin infection in an immunocompromised scuba (Pubmed Central) -  Nov 28, 2025   
    He had a history of psoriatic arthritis, treated with methotrexate and adalimumab for the last 5?years...He received antibiotics and topical steroids, and was switched from adalimumab to infliximab for a presumed diagnosis of pyoderma gangrenosum...This case represents a highly unusual cutaneous M. marinum presentation, with noncontiguous ulcerative lesions in an immunocompromised host. The diagnostic delay highlights the challenges of recognizing atypical nontuberculous mycobacterial infections, particularly in patients who are immunosuppressed.
  • ||||||||||  Humira (adalimumab) / AbbVie
    Journal:  Transarterial Embolization for Refractory Ankle Synovitis in an Adult Patient With a History of Juvenile Idiopathic Arthritis. (Pubmed Central) -  Nov 27, 2025   
    The patient was treated with adalimumab and had no evidence of active arthritis at other sites...Selective transarterial embolization of the malleolar branch of the anterior tibial artery was therefore performed, resulting in marked improvement in pain and swelling. In conclusion, transarterial embolization proved feasible and led to meaningful short-term clinical benefit, supporting its potential as an adjunctive therapeutic option in carefully selected cases of residual refractory ankle arthritis.
  • ||||||||||  Remicade (infliximab) / J&J, Humira (adalimumab) / AbbVie
    Review, Journal:  Severe liver injury due to infliximab therapy and adalimumab. (Pubmed Central) -  Nov 27, 2025   
    In contrast with the severe liver injury described in patients treated with infliximab, no cases of acute liver failure due to adalimumab requiring liver transplantation have been reported. However, subacute liver failure due to hepatitis B reactivation have been reported associated with adalimumab therapy and one case of subacute liver failure with adalimumab has been described in a patient without concomitant hepatitis B.
  • ||||||||||  Humira (adalimumab) / AbbVie, methylprednisolone sodium succinate / Generic mfg.
    Journal:  Unmasking Neurosarcoidosis in a Patient With Acute Meningitis Features. (Pubmed Central) -  Nov 27, 2025   
    We report the case of a 32-year-old man with a background history of Crohn's disease treated with Adalimumab who presented with a 10-day history of worsening headache, confusion, and new-onset seizures...After multidisciplinary team review, high-dose intravenous methylprednisolone was commenced, followed by an oral prednisolone taper, leading to significant symptomatic improvement...Early multidisciplinary involvement, systematic exclusion of infection and malignancy, and timely initiation of immunosuppression were critical to achieving a favourable outcome in this case. Clinicians should maintain a high suspicion for neurosarcoidosis in patients presenting with atypical neurological features, as early recognition and treatment may substantially alter prognosis.
  • ||||||||||  Remicade (infliximab) / J&J, Humira (adalimumab) / AbbVie
    Review, Journal:  Therapeutic Drug Monitoring in Special Circumstances in Inflammatory Bowel Disease. (Pubmed Central) -  Nov 27, 2025   
    These include inflammatory burden, bodyweight, age, disease phenotype, and route of administration, all of which are important considerations for individualising treatment in inflammatory bowel disease. This narrative review explores how special clinical situations-acute severe ulcerative colitis, perianal fistulising Crohn's disease, hypoalbuminaemia, extremes of body composition, pregnancy, paediatrics, and advanced age-alter drug pharmacokinetics and influence the utility and interpretation of therapeutic drug monitoring in inflammatory bowel disease.
  • ||||||||||  Humira (adalimumab) / AbbVie
    Journal:  Experiences of People Living with a Kidney Transplant: A Phenomenological Study. (Pubmed Central) -  Nov 27, 2025   
    The five themes, including (1) having new life and life satisfaction, (2) fear of kidney rejection and complications, (3) gratitude and spiritual practices, (4) concerns for the high cost of healthcare expenses, and (5) patience with self-management and resilience. We suggest that holistic, financial, and culturally congruent care should be implemented among people undergoing kidney transplantation to promote resilience and a longer life.
  • ||||||||||  Journal:  Successful treatment of pustulotic arthro-osteitis with bimekizumab: A case report. (Pubmed Central) -  Nov 25, 2025   
    The patient became afebrile the day after switching to BKZ, and both joint and skin symptoms gradually improved thereafter, along with normalization of laboratory markers. This case highlights the potential utility of BKZ in the treatment of refractory PAO, particularly in cases with systemic inflammation and fever.
  • ||||||||||  Humira (adalimumab) / AbbVie
    Journal:  A Label-Free blocking immunoassay to evaluate Anti-Adalimumab antibody activity in clinical samples. (Pubmed Central) -  Nov 24, 2025   
    The LF-BIA may provide an efficient approach to specifically measure blocking ADAs rather than total ADAs. Alongside with previously reported applications of label-free immunoassays in clinical testing, the LF-BIA highlights a promising area in which label-free technologies such as BLI can play an important role.
  • ||||||||||  Journal:  Tocilizumab as a treatment tool for ROSAH syndrome: a case report. (Pubmed Central) -  Nov 21, 2025   
    Broader clinical studies are needed to confirm efficacy. This case also highlights the importance of including ALPK1 in genetic panels for optic neuropathies, retinal disorders, and unexplained arthropathies to improve diagnosis and treatment strategies.
  • ||||||||||  Remicade (infliximab) / J&J, Humira (adalimumab) / AbbVie
    PK/PD data, Journal:  STRATIfy-PK SCORE: A predictive tool for identifying pharmacokinetic failure risk in anti-TNF-treated patient. (Pubmed Central) -  Nov 21, 2025   
    This case also highlights the importance of including ALPK1 in genetic panels for optic neuropathies, retinal disorders, and unexplained arthropathies to improve diagnosis and treatment strategies. STRATIfy-PK SCORE allows early identification of patients at high risk of pharmacokinetic failure and may support proactive, personalized TDM strategies to improve clinical outcomes.
  • ||||||||||  Stelara (ustekinumab) / J&J, Humira (adalimumab) / AbbVie
    Journal:  Serum Protein Profiles Differ with Adalimumab and Ustekinumab Treatment in Moderately to Severely Active Crohn's Disease. (Pubmed Central) -  Nov 19, 2025   
    P3
    Although patients receiving either adalimumab or ustekinumab reached similar rates of clinical remission at Week 52, the two therapies resulted in unique serum proteomic expression profiles reflecting mechanistic differences. Long-term treatment data is necessary to understand how differences in therapeutic mechanisms are associated with maintenance of remission and changes in patient reported outcomes in the context of inflammatory biomarkers.
  • ||||||||||  Journal:  Crohn's disease exacerbated by ghost pills of upadacitinib. (Pubmed Central) -  Nov 19, 2025   
    The disease activity was difficult to control with infliximab...She was subsequently introduced to several biologic agents, including adalimumab, ustekinumab, and vedolizumab: All failed to maintain long-term endoscopic and clinical remission...When using an extended-release agent such as UPA in patients with CD, the patient's gastrointestinal condition must be considered. Moreover, appropriate information must be shared with other health care professionals.
  • ||||||||||  Journal, Adverse events:  Interleukin-17 Inhibitors and Early Major Adverse Cardiovascular Events. (Pubmed Central) -  Nov 19, 2025   
    inhibitors (adalimumab or etanercept) for similar indications (psoriasis, psoriatic arthritis, ankylosing spondylitis, or juvenile arthritis), as an active comparator...In this case-time-control study based on a national insurance database, there was no evidence of a significant association between MACEs and the initiation of IL-17(R)A inhibitors, regardless of the individual cardiovascular risk of the patient. However, a modest risk increase cannot be entirely excluded.
  • ||||||||||  Humira (adalimumab) / AbbVie
    Journal:  Risk of Serious Infection With Adalimumab in Hidradenitis Suppurativa Compared With Psoriasis. (Pubmed Central) -  Nov 19, 2025   
    In this cohort study, among adults treated with adalimumab, those with moderate to severe HS had an elevated risk of infection and different infection profiles compared with those with psoriasis. Future research should focus on the impacts of disease severity and treatment regimens on infection risk and develop targeted prevention strategies.
  • ||||||||||  Velsipity (etrasimod) / Pfizer
    Trial completion date, Trial initiation date, Trial primary completion date:  EFFECT-1LAT: Describing Treatment Patterns and Creating an Updated Treatment Flow in an Ulcerative Colitis Population (clinicaltrials.gov) -  Nov 19, 2025   
    P=N/A,  N=4000, Not yet recruiting, 
    Delayed and failed MTX treatment as well as delayed switching to biologics often required subsequent eye surgery. Trial completion date: Oct 2025 --> Mar 2026 | Initiation date: Sep 2025 --> Dec 2025 | Trial primary completion date: Oct 2025 --> Mar 2026
  • ||||||||||  Humira (adalimumab) / AbbVie
    Journal:  Machine learning-accelerated 1H NMR quantification for bioprocess metabolite monitoring in monoclonal antibody production. (Pubmed Central) -  Nov 16, 2025   
    This study proposes a novel NMR spectral analysis strategy based on machine learning, successfully developing rapid quantitative models for 20 key metabolites in adalimumab biosimilar production process...The obtained optimal models for each metabolite exhibited great model performance with regression coefficients (R2) above 0.92 and residual prediction deviation (RPD) values exceeding 3.6. This study provides a reliable tool for intelligent monitoring of mAb production process, which can help ensure bioprocess consistency, improve yield and product quality, and ultimately reduce cultivation costs.
  • ||||||||||  Stelara (ustekinumab) / J&J, Humira (adalimumab) / AbbVie
    Review, Journal:  From reactive to predictive: Advancing biologic dosing in dermatology. (Pubmed Central) -  Nov 14, 2025   
    Model-informed precision dosing represents a paradigm shift in biologic therapy management, moving from standardised to dynamic, patient-centric dosing. By combining real-time monitoring, digital tools, and biological profiling, MIPD has the potential to maximise clinical response, minimise toxicity, and enhance the sustainability of long-term biologic treatment in dermatology.